Novel inhalation therapies for rare lung diseases

Giving lung patients with unmet medical needs an option.


First patient dosed in Serendex’s pivotal trial for PAP

Serendex’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its... Read More →
12May 16

Serendex signs license agreement with Japanese partner

Serendex Pharmaceuticals A/S signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference... Read More →

GM-CSF & Factor VIIa

We develop inhalable medicines for the treatment of patients with severe pulmonary conditions. We focus on two biologic compounds – GM-CSF and Factor VIIa.

About our focus

Respiratory conditions

We focus on respiratory conditions such as PAP (pulmonary alveolar proteinosis), ARDS (acute respiratory distress syndrome) and DAH (diffuse alveolar hemorrhage).

See overview

Serendex at a glance

The what, who, where, why and how for Serendex Pharmaceuticals A/S. Learn more about our company by reading our corporate factsheet.

Download factsheet

Annual Results 2015

Get up to date on Serendex Pharmaceuticals A/S. Download our Annual Report 2015 and read more about our pipeline progress and business outlook.

Annual Report 2015

PAP Information Brochure

Learn more about or key indication PAP (pulmonary alveolar proteinosis) by reading this information brochure developed in collaboration with medical experts.

Read brochure

Back to Top